PortalPublikationenFunding HIV-vaccine research in developing countries-what is...

Funding HIV-vaccine research in developing countries-what is wrong with IAVI's recommendation?

Standard

Funding HIV-vaccine research in developing countries-what is wrong with IAVI's recommendation? / Sonntag, Diana.

in: HEALTH ECON, Jahrgang 23, Nr. 2, 01.02.2014, S. 141-58.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sonntag, D 2014, 'Funding HIV-vaccine research in developing countries-what is wrong with IAVI's recommendation?', HEALTH ECON, Jg. 23, Nr. 2, S. 141-58. https://doi.org/10.1002/hec.2909

APA

Sonntag, D. (2014). Funding HIV-vaccine research in developing countries-what is wrong with IAVI's recommendation? HEALTH ECON, 23(2), 141-58. https://doi.org/10.1002/hec.2909

Vancouver

Sonntag D. Funding HIV-vaccine research in developing countries-what is wrong with IAVI's recommendation? HEALTH ECON. 2014 Feb 1;23(2):141-58. https://doi.org/10.1002/hec.2909

Bibtex

@article{ade02aa26dd04eedacbd107c5d44c7ea,
title = "Funding HIV-vaccine research in developing countries-what is wrong with IAVI's recommendation?",
abstract = "The International AIDS Vaccine Initiative recommends targeting resources to research institutions in developing countries in order to accelerate the development of an effective HIV vaccine. In contrast, this paper shows that neither lump-sum nor in-kind transfers are an effective policy. We analyze several financing mechanisms as a means to overcome the lack of depth in HIV-vaccine research in a non-cooperative framework. At first, we point to cases in which financial support is actually counterproductive. Then we analyze whether in-kind transfers are preferable to lump-sum transfers. Even if donors prefer aid in kind because the incentives for moral hazard of recipients can be reduced, we demonstrate that it is effective only if recipients have cost advantages.",
keywords = "AIDS Vaccines, Biomedical Research, Developing Countries, Drug Industry, Global Health, Humans, International Cooperation, Models, Economic, Research Personnel, Research Support as Topic",
author = "Diana Sonntag",
note = "Copyright {\textcopyright} 2013 John Wiley & Sons, Ltd.",
year = "2014",
month = feb,
day = "1",
doi = "10.1002/hec.2909",
language = "English",
volume = "23",
pages = "141--58",
journal = "HEALTH ECON",
issn = "1057-9230",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Funding HIV-vaccine research in developing countries-what is wrong with IAVI's recommendation?

AU - Sonntag, Diana

N1 - Copyright © 2013 John Wiley & Sons, Ltd.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - The International AIDS Vaccine Initiative recommends targeting resources to research institutions in developing countries in order to accelerate the development of an effective HIV vaccine. In contrast, this paper shows that neither lump-sum nor in-kind transfers are an effective policy. We analyze several financing mechanisms as a means to overcome the lack of depth in HIV-vaccine research in a non-cooperative framework. At first, we point to cases in which financial support is actually counterproductive. Then we analyze whether in-kind transfers are preferable to lump-sum transfers. Even if donors prefer aid in kind because the incentives for moral hazard of recipients can be reduced, we demonstrate that it is effective only if recipients have cost advantages.

AB - The International AIDS Vaccine Initiative recommends targeting resources to research institutions in developing countries in order to accelerate the development of an effective HIV vaccine. In contrast, this paper shows that neither lump-sum nor in-kind transfers are an effective policy. We analyze several financing mechanisms as a means to overcome the lack of depth in HIV-vaccine research in a non-cooperative framework. At first, we point to cases in which financial support is actually counterproductive. Then we analyze whether in-kind transfers are preferable to lump-sum transfers. Even if donors prefer aid in kind because the incentives for moral hazard of recipients can be reduced, we demonstrate that it is effective only if recipients have cost advantages.

KW - AIDS Vaccines

KW - Biomedical Research

KW - Developing Countries

KW - Drug Industry

KW - Global Health

KW - Humans

KW - International Cooperation

KW - Models, Economic

KW - Research Personnel

KW - Research Support as Topic

U2 - 10.1002/hec.2909

DO - 10.1002/hec.2909

M3 - SCORING: Journal article

C2 - 23355491

VL - 23

SP - 141

EP - 158

JO - HEALTH ECON

JF - HEALTH ECON

SN - 1057-9230

IS - 2

ER -